Dr Reddy's Labs Q2 Results: Profit rises 33% YoY to Rs 1,480 crore, revenue up 9%The company reported an EBITDA of Rs 2,181 crore in the September quarter, higher by 13% YoY. EBITDA margins in the same period came in at ...
27 Oct, 2023, 04.19 PM IST
Dr Reddy's Q1 Results: Net profit rises 18% YoY to Rs 1403 croreIndian drug company Dr Reddy's plans to use its net cash surplus of INR 5,000 crore ($670m) to fund acquisitions and innovations aiming at ...
26 Jul, 2023, 08.46 PM IST
Dr Reddy's Q1 Results: PAT up 18% YoY at Rs 1,405 crore, tops estimateThe EBITDA or earnings before interest, taxes, depreciation, and amortisation, for the quarter increased 20% on year to Rs 2,137 crore. How...
26 Jul, 2023, 04.24 PM IST
Dr Reddy's to acquire Mayne Pharma US generic portfolio for $105 millionUnder the terms of the agreement, Dr. Reddy’s will acquire the portfolio for an upfront payment of $90 million in cash, contingent payments...
27 Feb, 2023, 12.48 PM IST
Alembic Pharma gets USFDA nod for generic drugDoxycycline Hyclate delayed-release tablets are indicated to reduce the development of drug resistant bacteria.
04 Jan, 2022, 05.45 PM IST
Pharma stocks crash after US lawsuit over price manipulationsThe other generic makers named in the suit include Apotex, Teva, Heritage Pharma and Par Pharma.
14 May, 2019, 08.46 AM IST
Indian execs 'named' in US pharma caseThe Indian generic makers named in the lawsuit are Aurobindo, Dr Reddy’s, Emcure, Glenmark, and Zydus.
11 Apr, 2019, 10.11 AM IST
Oil collapse hits Australian shares, but NZ up; Fed in focusAustralia's S&P/ASX 200 index declined 0.2 per cent or 8.9 points to close at 5,580.60.
19 Dec, 2018, 01.25 PM IST
Australian shares end higher, healthcare stocks at record; NZ closedThe S&P/ASX 200 index rose 0.6 percent or 35.100 points to 6025.500.
04 Jun, 2018, 01.07 PM IST
US probe against generic drugs overblown: ExpertsThe DoJ has in the past probed multinational drug companies for inappropriate marketing practices but the scale of investigations against t...
08 Nov, 2016, 12.25 AM IST
DRL, Cipla, Aurobindo among others to buy products from TevaThe remedy requires Teva to divest the drug portfolio to 11 firms and marks the largest drug divestiture order in an FTC pharmaceutical mer...
29 Jul, 2016, 03.41 PM IST
- US-based Hospira to buy Orchid Chemicals' injectables biz for $400 mn
Orchid Chemicals & Pharmaceuticals to sell its injectables business to the US-based Hospira for around $400 million.
16 Dec, 2009, 04.37 AM IST
- Sanofi to eclipse Sun’s Eloxatin plan
France’s largest pharma company, Sanofi-Aventis, is suing India’s Sun Pharmaceuticals and Hospira’s Mayne Pharma to prevent the latter from...
26 Jul, 2007, 02.42 AM IST
- Ranbaxy's Simvastatin to go Down Under by Aug
Ranbaxy Laboratories is planning to launch cardiovascular drug Simvastatin in Australia this year.
21 Jul, 2007, 03.07 AM IST
- Windfall for cos eyeing US oncology market
With anti-cancer blockbuster drugs set to go off-patent in the US in the next three to four years, generic players are gearing up to tap th...
11 Apr, 2007, 02.54 AM IST
- Hospira-Mayne deal likely to alter pharma equations here
One of the biggest trans-continent deals in the generic pharma sector is likely open the floodgates of opportunities for the Indian pharma ...
22 Sep, 2006, 01.27 AM IST
- Claris enters pact with Mayne, Sandoz
Continuing with its overseas expansion plans, Ahmedabad-based pharmaceutical firm Claris Lifesciences today said it had entered into strate...
02 Aug, 2006, 09.20 PM IST